Clinical Trial Update: Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC [Phase 4]

View source ↗

Summary

Phase 4 trial update investigating Radium-223 combined with dexamethasone as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Radium-223 (radium-223 dichloride)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Metastatic Prostate Cancer | Phase 4 | Status: UNKNOWN